TuHURA Biosciences (TuHURA Biosciences) Net Margin % : 0.00% (As of Dec. 2022)

View and export this data going back to 2050. Start your Free Trial

What is TuHURA Biosciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. TuHURA Biosciences's Net Income for the six months ended in Dec. 2022 was $-9.37 Mil. TuHURA Biosciences's Revenue for the six months ended in Dec. 2022 was $0.00 Mil. Therefore, TuHURA Biosciences's net margin for the quarter that ended in Dec. 2022 was 0.00%.

The historical rank and industry rank for TuHURA Biosciences's Net Margin % or its related term are showing as below:

HURA's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -154.15
* Ranked among companies with meaningful Net Margin % only.

TuHURA Biosciences Net Margin % Historical Data

The historical data trend for TuHURA Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Net Margin % Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Net Margin %

TuHURA Biosciences Semi-Annual Data
	Dec21	Dec22
Net Margin %	-	-

Competitive Comparison of TuHURA Biosciences's Net Margin %

For the Biotechnology subindustry, TuHURA Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's Net Margin % falls into.

TuHURA Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

TuHURA Biosciences's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-9.368	/	0
	=	%

TuHURA Biosciences's Net Margin for the quarter that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	-9.368	/	0
	=	%

TuHURA Biosciences (NAS:HURA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

TuHURA Biosciences Net Margin % Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences (TuHURA Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

TuHURA Biosciences Inc is a clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies. The company's lead personalized cancer vaccine candidate, IFx-Hu2.0, is designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria. Through an intratumoral injection of a gene coding for emm55, an immunogenic bacterial protein that is then expressed on the surface of tumor cells, the immune system is activated, providing a potent, multivalent systemic response against all neoantigens in a patient's tumor.

TuHURA Biosciences (TuHURA Biosciences) Headlines

No Headlines